Soligenix receives EU orphan drug status for Behçet's disease treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Soligenix receives EU orphan drug status for Behçet's disease treatment
Soligenix, Inc. (NASDAQ: SNGX) Delayed: 0.43 --0 (-0%)
Previous Close $0.43    52 Week High $4.35 
Open $0.44    52 Week Low $0.44 
Day High $0.45    P/E N/A 
Day Low $0.43    EPS $-0.81 
Volume 626,312